## Fiscal Year 2012 (FY12) Duchenne Muscular Dystrophy Research Program (DMDRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Investigator-Initiated Research Award Go to: • <u>Program Announcement</u> • <u>Application Instructions and</u> <u>General Information</u> Grants.gov Funding Opportunity Number: <u>W81XWH-12-DMDRP-IIRA</u>	<ul> <li>Principal Investigator: Must be at or above the level of Assistant Professor (or equivalent)</li> <li>Optional Qualified</li> <li>Collaborator: Must be at or above the level of Assistant Professor (or equivalent)</li> <li>Optional Nested Resident or Medical Student Trainee:</li> <li>Resident trainee must be enrolled in an accredited residency program. Medical student trainee must be enrolled in a nationally accredited (or equivalent)</li> <li>medical school. Trainees must be able to devote a minimum of 40% level of effort.</li> </ul>	<ul> <li>Supports translational research that will have an impact on extending and improving the function, quality of life, and life span for all individuals diagnosed with DMD</li> <li>Preliminary data required</li> <li>Clinical trials not allowed</li> </ul>	<ul> <li>Maximum period of performance is 3 years</li> <li>Maximum allowable funding is \$525K in direct costs (\$675K in direct costs if requesting an Optional Collaborator)</li> <li>Nested traineeship: Additional maximum of \$75K for residents or \$55K for medical students in direct and indirect costs over a one-year period of performance</li> </ul>	Pre-application (Preproposal): July 25, 2012 5:00 p.m. Eastern time (ET) Invitation to Submit an Application: September 2012 Application: November 7, 2012 11:59 p.m. ET
Therapeutic Idea Award         Go to:         • Program Announcement         • Application Instructions and General Information         Grants.gov Funding         Opportunity Number:         W81XWH-12-DMDRP-TIA	<b>Independent Investigator</b> at or above the level of Assistant Professor (or equivalent)	<ul> <li>Supports early-stage research relative to novel therapeutic development for DMD</li> <li>Innovation and impact are primary criteria</li> <li>Preliminary data are not required</li> <li>Studies should be hypothesis- based</li> </ul>	<ul> <li>Maximum period of performance is 2 years</li> <li>Maximum allowable funding for the entire period of performance is \$300K in direct costs</li> </ul>	Pre-application (Preproposal): July 25, 2012 5:00 p.m. Eastern time (ET) Invitation to Submit an Application: September 2012 Application: November 7, 2012 11:59 p.m. ET